EichorEICHOR
Location: S O Paulo Synced from ClinicalTrials.gov · August 08, 2026

Clinical studies recruiting near S O Paulo

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · Pfizer · NCT06758401Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS
Phase 3 · Eli Lilly and Company · NCT06890598A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants Wit
Phase 3 · Merck Sharp & Dohme LLC · NCT06077760EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Phase 3 · Boehringer Ingelheim · NCT06531824A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Phase 3 · Janssen Research & Development, LLC · NCT06319820Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesop
Phase 3 · Daiichi Sankyo · NCT06731478A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KR
Phase 3 · Eli Lilly and Company · NCT06119581A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Phase 3 · Daiichi Sankyo · NCT06203210Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in
Phase 3 · Merck Sharp & Dohme LLC · NCT03486873A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-108
Phase 3 · Merck Sharp & Dohme LLC · NCT06997497A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Signif
Phase 2/Phase 3 · Pfizer · NCT06989437A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Particip
Phase 3 · Bayer · NCT06452277A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Parti
Phase 3 · Merck Sharp & Dohme LLC · NCT06312137Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participa
Phase 3 · Amgen · NCT06252649Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-sm
Phase 3 · Daiichi Sankyo · NCT06899126A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3 · Merck Sharp & Dohme LLC · NCT06966700Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Phase 2 · Merck Sharp & Dohme LLC · NCT04728893A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to
Phase 2 · Takeda · NCT06233461A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasiv
Phase 3 · Janssen Research & Development, LLC · NCT06919965A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participan
Phase 3 · Mirati Therapeutics Inc. · NCT06875310A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild
Phase 3 · Janssen Research & Development, LLC · NCT06750094EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes,
Phase 3 · Boehringer Ingelheim · NCT07064473A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-L
Phase 3 · Amgen · NCT05920356A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Phase 2/Phase 3 · Janssen Research & Development, LLC · NCT07196722A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High
Phase 3 · Stemline Therapeutics, Inc. · NCT06492616Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (
Phase 2/Phase 3 · CSL Behring · NCT05485961A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Di
Phase 3 · Merck Sharp & Dohme LLC · NCT06430801
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.